Welcome to our dedicated page for Raphael Pharm news (Ticker: RAPH), a resource for investors and traders seeking the latest updates and insights on Raphael Pharm stock.
Raphael Pharmaceutical Inc. (RAPH) is a clinical-stage biotechnology company focused on cannabinoid-based therapies for inflammatory and autoimmune diseases. Its news flow centers on clinical trial progress, patent activity, and developments in its research collaboration with the Medical Cannabis Research and Innovation Center at Rambam Health Care Campus.
Investors and healthcare observers following Raphael Pharmaceutical’s news can track updates on its lead rheumatoid arthritis program, including proof-of-concept clinical study results for its highly purified, non-psychoactive cannabinoid-based formula. The company has reported improvements in pain, sleep quality, and overall well-being in an eight-week RA study, as well as changes in Disease Activity Score (DAS28) and patient-reported satisfaction, with no adverse effects observed in that trial.
News items also cover intellectual property milestones, such as the filing of a provisional patent application with the United States Patent and Trademark Office for the use of Raphael Pharmaceutical’s cannabinoid-based technology platform in neutrophil-dominant autoimmune diseases. This includes indications like rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, systemic lupus erythematosus with neutrophil involvement, and gout.
Additional updates may highlight preclinical findings in chronic lung inflammation, shareholder communications outlining the company’s mission and asset-light business model, and potential partnering or licensing strategies. For those monitoring RAPH, this news page provides a centralized view of announcements related to its clinical-stage pipeline, research partnerships, and cannabinoid-focused drug development efforts.
Raphael Pharmaceutical (OTCQB: RAPH) filed a provisional patent application (No. 63/911,729) on Nov 17, 2025 for its highly purified, THC‑free/CBD‑free cannabinoid platform targeting neutrophil‑dominant autoimmune diseases, including rheumatoid arthritis (RA).
The filing was joint with Rambam Health Care Campus and follows an IRB‑approved eight‑week U.S. proof‑of‑concept study that reported significant improvements in pain, sleep, well‑being and a DAS28 reduction from high to moderate disease severity, with no adverse effects reported. The company describes RaphaWell as an orally delivered, non‑psychoactive candidate moving toward initial commercial launch.
Raphael Pharmaceutical (OTCQB: RAPH) announced positive proof-of-concept clinical study results for its cannabinoid-based formula treating rheumatoid arthritis (RA). The study, conducted by Citruslabs under IRB approval, showed significant improvements in 12 adult participants over eight weeks.
Key findings include a 19.2% reduction in Disease Activity Score (DAS28), shifting patients from high to moderate disease activity. The percentage of participants in remission increased from 0% to 16.67%, while high disease activity cases decreased from 66.67% to 41.67%. Pain-related symptoms improved, with negative pain outcomes dropping from 75% to 50%, and morning stiffness decreased from 75% to 41.67%.
83.33% of participants expressed desire to continue treatment, and 91.67% would recommend it to others. The company aims to potentially partner with a global biopharma company for drug delivery format development and commercialization.
Raphael Pharmaceutical, a clinical-stage biotechnology company, is advancing a novel cannabinoid-based research platform. The company highlights its exclusive relationship with Rambam Health Care Campus, which provides cutting-edge facilities for cannabinoid research. Raphael's lead product candidate, HPC1, targets rheumatoid arthritis and has shown promise in preclinical studies. A clinical study for HPC1 began in May 2024, with results expected by the end of the year. The company also explores cannabinoid treatments for chronic lung inflammation and aims to commence FDA Phase I trials in 2025. Raphael's mission is to offer cost-effective, accessible treatments for inflammatory diseases.